Clinical Hepatology Update Live 2019
- Registration Closed
The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.
Core Competencies:
Patient Care and Procedural Skills
Provide Patient-centered Care
Values/Ethics for Interprofessional Practice
Medical Knowledge
Work in Interdisciplinary Teams
Roles/Responsibilities
Practice-based Learning and Improvement
Employ Evidence-based Practice
Interprofessional Communication
Interpersonal and Communication Skills
Apply Quality Improvement
Teams and Teamwork
Systems-based Practice
Program Chairs:
Marcelo Kugelmas, MD, FAASLD
Elizabeth K. Goacher, PA-C, MHS
Janice Jou, MD, MHS
Lisa Catalli, MSN, NP-B
CME Hours: 13.00 AMA PRA Category 1 Credits
MOC Points: 13.00 MOC Points
Continuing Education (Nursing Credits): 13.00 Contact Hours
Pharmacology: 1.25 Pharmacology Credits
How to access your CME Certificate from the Clinical Hepatology Update 2019:
1. Click HERE and login if you are not already logged in.
2. Complete the Course Evaluation.
3. Print the Certificate of Attendance.
4. Attest to the EACH session you attended at the conference. (You will simply click on the session you attended, attest and receive credit. Please note: the credits earned will be applied to your cohesive CME Certificate which will have all session completed credits on it.)
5. Click the View CME Certificate tab on the top of the Package. You can also access your CME Certificate at the bottom of the page.
6. For ABIM MOC, complete the MOC evaluation and ensure your ABIM ID and birthday are in your LiverLearning® Profile.
If you have any questions regarding the CME and or MOC process,
please contact education@aasld.org.
If you have any technical questions, please contact online_education@aasld.org.
- To understand and describe the current standard of care for the diagnosis and management of non-alcoholic fatty liver disease.
- Manage patients with complications of portal hypertension.
- Recognize when decompensated cirrhosis patients are appropriate candidates for palliative care and hospice referral.
- Hepatologists
- Gastroenterologists
- Nurses
- Nurse Practitioners
- Physician Assistants
- Transplant Coordinators
- Fellows/Trainees
Jasmohan Bajaj, MD, FAASLD
Bryan Balmadrid, MD
Stephen Caldwell, MD, FAASLD
Lisa Catalli, MSN, NP-BC
Michael Chang, MD, MSc, MBA, FAASLD
Kathleen Corey, MD, MPH, MMSc
Khashayar Farsad, MD
Jaquelyn Fleckenstein, MD, FAASLD
Catherine Frenette, MD
Richard Gilroy, MD
Robert Gish, MD, FAASLD
Elizabeth Goacher, PA-C, MHS
Janice Jou, MD, MHS
Marcelo Kugelmas, MD, FAASLD
Jennifer Lai, MD
Anne Larson, MD, FAASLD
Michael Leise, MD
Cynthia Levy, MD, FAASLD
Willscott Naugler, MD, FAASLD
Jody Olson, MD
Arpan Patel, MD
Sonali Paul, MD
K Rajender Reddy, MD, FAASLD
Puneeta Tandon, MD, FRCPC
Elliot Tapper, MD
Robert Weinrieb, MD
Disclosures
This live educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the Clinical Hepatology Update faculty and the Clinical Research Committee and Governing Board.
As an accredited provider, AASLD requires individuals involved in the planning of continuing medical education (CME) activities to disclose all financial relationships, including those of their spouse or partner, with a commercial interest within the past 12 months. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. All conflicts of interest are resolved prior to participation.
Faculty Disclosures
Jasmohan Bajaj, MD, FAASLD
Advisory Board and/or Committee and Review Panels: Valeant, Norgine, Intercept
Honoraria for CME Activities: Integrity CE. CLD communications
Grants/Research Support: Valeant
Bryan Balmadrid, MD
Nothing to disclose
Stephen Caldwell, MD, FAASLD
Grant/Research Support: Genfit, TaiwanJ, Immuron, Gilead Sciences, Immuron, NGM, Mallinckrodt, Conatus, Galmed, Vital Therapy
Lisa Catalli, MSN, NP-BC
Nothing to disclose
Michael Chang, MD, MSc, MBA, FAASLD
Nothing to disclose
Kathleen Corey, MD, MPH, MMSc
Speaking and Teaching: Synageva; Scientific Consulting: Novo Nordisk
Khashayar Farsad, MD
Scientific Consulting: Cook Medical, Neuwave Medical; Grants/Research Support: Guerbet, LLC
Leadership in related society: American Society of Digestive Disease Interventions (consensus panel committee)
Jaquelyn Fleckenstein, MD, FAASLD
Nothing to disclose
Catherine Frenette, MD
Scientific Consulting: Bayer, Intercept; Speakers Bureau: Bayer, Gilead
Richard Gilroy, MD
Speakers Bureau: Novartis, Gilead, Salix
Robert Gish, MD, FAASLD
Scientific Consulting: Abbot, AbbVie, Alexion, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Contravir, Eiger, Enyo, eStudySite, Genentech, Gilead Sciences, HepaTX, HepQuant, Hoffmann-LaRoche Ltd., Intellia, Intercept, Ionis Pharmaceuticals, Janssen, MedImmune, Merck, Shionogi, Transgene, Trimaran
Leadership in related society: AbbVie, Merck, Arrowhead, Bayer, Contravir, Dova Pharmaceuticals, Eiger, Enyo, Janssen, Medimmune, Janssen/J&J, Intercept, Shionogi, Spring Bank, Ionis
Speakers Bureau: Alexion, Bayer, BMS, Dova, Gilead Sciences Inc., AbbVie, Merck
Elizabeth Goacher, PA-C, MHS
Scientific Consulting: Gilead Pharmaceuticals, AbbVie Pharmaceuticals
Speakers Bureau: AbbVie Pharmaceticals, Gilead Pharmaceuticals
Janice Jou, MD, MHS
Nothing to disclose
Marcelo Kugelmas, MD, FAASLD
Speakers Bureau: Intercept, Dova, Merck, Gilead, Abbvie, Salix
Scientific Consulting: Gilead, Abbvie, Merck, Salix, Shinogi, Dova, Intercept, Mallinkrodt Grants/Research Support: Novartis, Enanta, Tobira, Pfizer, Madrigal, Genfit, Shire, Cirius, Intercept, Dova, Gilead
Jennifer Lai, MD
Scientific Consulting: Third Rock Ventures, LLC, Axcella
Anne Larson, MD, FAASLD
Nothing to disclose
Michael Leise, MD
Nothing to disclose
Cynthia Levy, MD, FAASLD
Grants/Research Support: Intercept, Gilead, GSK, Novartis, Genfit, CymaBay, Enanta, Arena, Durect, High Tide, Eli Lilly
Scientific Consulting: Target Pharma Solutions, Pliant, Cara Therapeutics
Leadership in related society: Associate Editor- Liver Transplantation
Willscott Naugler, MD, FAASLD
Nothing to disclose
Jody Olson, MD
Nothing to disclose
Arpan Patel, MD
Nothing to disclose
Sonali Paul, MD
Nothing to disclose
K Rajender Reddy, MD, FAASLD
Grant/Research Support: AbbVie,Gilead, Janssen, Merck, Intercept, Mallinckrodt, Conatus, Novartis
Puneeta Tandon, MD, FRCPC
Advisory Committee and/or Review Panels: Lupin Pharma Canada
Elliot Tapper, MD
Grants/Research Support: Valeant, Gilead
Scientific Consulting: Novartis
Robert Weinrieb, MD
Nothing to disclose
Planning Committee Disclosures
Curtis K. Argo, MD, MS, FAASLD (Maintenance of Certification Committee)
Nothing to disclose
Meena B. Bansal, MD, FAASLD (Governing Board)
Nothing to disclose
Jorge A. Bezerra, MD, FAASLD (Governing Board)
Grant/Research Support: Shyer, Gilead
Mamatha Bhat (Clinical Research Committee)
Nothing to disclose
Therese Bittermann, MD (Clinical Research Committee)
Nothing to disclose
Kenneth D. Chavin, MD, PhD (Clinical Research Committee)
Nothing to disclose
Raymond Chung, MD, FAASLD (Governing Board; Maintenance of Certification Committee)
Grant/Research Support: AbbVie, BMS, Merck, Boehringer Ingelheim, Gilead, Janssen
Other: DSMB – Alnylam
Laurie DeLeve, MD, PhD, FAASLD (Governing Board)
Consulting: Daiichi Sankyo; Seagen; Pfizer
Edward Doo, MD (Clinical Research Committee)
Nothing to disclose
Robert J. Fontana, MD, FAASLD (Clinical Research Committee)
Grants/Research Support: BMS, Gilead, Abbvie
Consulting: Sanofi
Kimberly A Forde, MD, MHS (Clinical Research Committee)
Nothing to disclose
Michael W. Fried, MD, FAASLD (Governing Board)
Stock/Stock Options: TARGET PharmaSolutions
Consulting: AbbVie, BMS, Merck, TARGET PharmaSolutions (All uncompensated)
Grant/Research Support: AbbVie, BMS, Gilead, Merck, National Institutes of Health
Debra Guss, DNP, RN, ANP-C (Maintenance of Certification Committee)
Nothing to disclose
Steven K. Herrine, MD, FAASLD (Maintenance of Certification Committee)
Grant/Research Support: Gilead, BMS, Galectin, Intercept
Vandana Khungar, MD, MSc (Maintenance of Certification Committee)
Nothing to disclose
Ayman A. Koteish, MD, FAASLD (Maintenance of Certification Committee)
Nothing to disclose
Paul Yien Kwo, MD, FAASLD (Clinical Research Committee)
Consulting: Gilead, Abbvie
Grants/Research Support: BMS, Abbvie
John R. Lake, MD, FAASLD (Governing Board)
Consulting: Vital Therapies, SRTR
Other: Intercept DSMB
Jennifer Cindy Lai, MD (Clinical Research Committee)
Consulting: Third Rock Ventures, LLC, Axcella
Rohit Loomba, MD (Clinical Research Committee)
Grants/Research Support: Allergan, BMS, BI, Daiichi-Sankyo Inc., Galectin, Galmed, GE, Genfit, Gilead, Intercept, Janseen Inc, Madrigal, Merck, NGM, Pfizer, Prometheus, Siemens, Sirius
Consulting: Bird Rock Bio, Celgene, Enanta, GRI Bio, Madrigal, Metacrine, NGM, Receptos, Sanofi, Arrowhead Research, Galmed, NGM, GIR, Inc. and Metacrine, Inc
Bruce A. Luxon, MD, PhD, FAASLD (Governing Board)
Board Membership: ACG Research Committee, Baxalta, DSMB
Consulting: National Hemophilia Foundation
Lopa Mishra, MD, FAASLD (Governing Board)
Grant/Research Support: NIH
Smruti R. Mohanty, MD, MS (Maintenance of Certification Committee)
Leadership in related society: Education Committee Member, the Alliance for Academic Internal Medicine (AAIM) (July 2016-19) Editorial Board, World Journal of Gastroenterology (2007-Present) Editorial Board, Digestive Disease & Science (2009-Present) Editorial Board, World Journal of Hepatology (2009-Present) Reviewer: Hepatology, Clinical Gastroenterology & Hepatology, Digestive Disease & sciences, Post Graduate Medical Journal, World Journal of Gastroenterology World journal of hepatology
Speaker's Bureau: Gilead Science, Merck, Abbvie and Intercept
David C. Mulligan, MD, FAASLD (Governing Board)
Nothing to disclose
Arpan A. Patel, MD (Clinical Research Committee)
Nothing to disclose
Heather M. Patton, MD, FAASLD (Maintenance of Certification Committee)
Grant/Research Support: Gilead Sciences
K. Gautham Reddy, MD, FAASLD (Maintenance of Certification Committee)
Leadership in related society: Board, Committee, Journal: Member, Training Committee: American College of Gastoneterology
Speaker's Bureau: Intercept Dova; Research Grants: Merck Intercept Genfit
Scientific Consulting: Advisor to Industry Commercial Enterprise, including Development of Educational Presentations: Intercept
Susan M. Salahshor, PhD, PA-C (Clinical Research Committee)
Nothing to disclose
Ronald J. Sokol, MD, FAASLD (Governing Board)
Consulting: Alexion; Albireo; Retrophin; Shire
Grant/Research Support: Lumena/Shire; FFF Enterprises
Grace L. Su, MD, FAASLD (Maintenance of Certification Committee)
Company Employee, Officer, Director: My husband and son have equity interest in Applied Morphomics and Prenovo
Shikha Sundaram, MD, MSCI (Clinical Research Committee)
Nothing to disclose
Ryan M. Taylor, MD (Maintenance of Certification Committee)
Speaker's Bureau: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Bristol-Myers Squibb, Merck, Inc., Abbvie, Inc.
Grant/Research Support: Conatus Pharmaceuticals, Gilead Sciences, Abbvie, Conatus Pharmaceuticals
Norah Terrault, MD, MPH, FAASLD (Governing Board; Clinical Research Committee)
Advisory Committees and/or Review Panels: Dova
Grant/Research Support: AbbVie, Gilead, BMS, Merck
Kymberly Watt, MD (Clinical Research Committee)
Other (eg. Expert testimony): Intercept - site- PI Gilead - site PI, co-I Conatus - site co-I Novartis - pr subanalysis Pfizer- site co-I all multicenter study related
Julia J. Wattacheril, MD, MPH (Clinical Research Committee)
Grants/Research Support: Conatus Pharmaceuticals, Genfit Pharmaceuticals, Galectin Therapeutics, Gilead Sciences, Intercept Pharmaceuticals
Staff Disclosures
Heather Carnahan
Nothing to disclose
Julie Deal
Nothing to disclose
Katie Duggan, BA
Nothing to disclose
Sharon Grant
Nothing to disclose
Janeil Klett
Nothing to disclose
Denise Seise
Nothing to disclose
Suzanne Thibeault
Nothing to disclose
Anne Wrobel
Nothing to Disclose
Credits Offered
Continuing Medical Education (CME): 13.00 AMA PRA Category 1 Credits™
Maintenance of Certification (MOC): 13.00 MOC Points
Continuing Education (CE): 13.00 Contact Hours
Pharmacology: 1.25 Pharmacology Credits
Accreditation and Designation Statements
Continuing Medical Education (CME)
The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 13.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 13.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.
Continuing Education (Nursing Contact Hours)
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 13.00 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Pharmacology Credits
The following presentations are also eligible for 1.25 pharmacotherapeutic hours:
The Other Side of the Triad: Non-Cirrhotic Portal Hypertension
Anticoagulation in Portal Hypertension
Back to the Basics: Hepatitis B Management
AIH: When to Change and If/When to Stop Therapy
Please note onsite documentation for identification of sessions eligible for pharmacotherapeutic hours and self-submit those to your board. Keep the agenda as a reference in case they have questions.
Claiming CME Credits
Physicians and other health care professionals seeking 13.00 AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Monday, July 15. A link to the CME and MOC evaluation will be emailed to attendees after the conference.
Claiming ABIM MOC Points
Physicians seeking ABIM and/or ABP MOC points must complete the CME and MOC evaluation by Monday, July 15. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.
MOC Points will be reported to the ABIM and ABP by the end of July 2019 for attendees who successfully complete the MOC evaluation.
Claiming CE Contact Hours and Pharmacology Credits
1. Go to http://aasld.cmecertificateonline.com
2. Click on the “2019 Clinical Hepatology Update” link
Please print all pages of your certificate for your record.
Questions? Email Certificate@AmedcoEmail.com
